Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for combination trial
In December, Gilead closed out a year-long spending spree on cancer drugs by closing a deal much closer to their roots: a $1.7 billion deal for a German biotech focused on hepatitis delta virus. It was a bet on a drug they’d watched for years and a signal, Gilead virology chief Diana Brainard said, that although they’ve spent billions on oncology, they’re not leaving the field that turned them into a behemoth.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.